Mechanistic Study of EBV mRNA Vaccine (WGc-043) in EBV-Positive Relapsed/Refractory Lymphoma
NCT ID: NCT06788600
Last Updated: 2025-04-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
15 participants
OBSERVATIONAL
2025-04-01
2026-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive Lymphoma
NCT07162012
Rituximab Monotherapy for EBV-HLH and CAEBV
NCT05384743
Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma
NCT01956084
Exploratory Study of a Novel Oncolytic Vaccinia Virus RGV004 in the Treatment of Refractory/Relapsed B-cell Lymphoma
NCT04887025
Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE)
NCT02973113
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
EBV mRNA vaccine infusion with a dose of 100 µg
Drug: EBV mRNA vaccine (WGc-043) Patients will receive a 100 µg dose of the EBV mRNA vaccine per administration, including 5 doses for the primary immunization regimen and subsequent optional personalized treatment. For the primary immunization, the first 4 doses will be administered weekly, with the 5th dose given 4 weeks after the 4th dose.
EBV mRNA vaccine (WGc-043)
Each subject will be infused with EBV mRNA vaccine per administration, including 5 doses for the primary immunization regimen and subsequent optional personalized treatment. For the primary immunization, the first 4 doses will be administered weekly, with the 5th dose given 4 weeks after the 4th dose.
The specific dose of mRNA vaccine will be determined according to the experimental group.
EBV mRNA vaccine infusion with a dose of 200 µg
Drug: EBV mRNA vaccine (WGc-043) Patients will receive a 200 µg dose of the EBV mRNA vaccine per administration, including 5 doses for the primary immunization regimen and subsequent optional personalized treatment. For the primary immunization, the first 4 doses will be administered weekly, with the 5th dose given 4 weeks after the 4th dose.
EBV mRNA vaccine (WGc-043)
Each subject will be infused with EBV mRNA vaccine per administration, including 5 doses for the primary immunization regimen and subsequent optional personalized treatment. For the primary immunization, the first 4 doses will be administered weekly, with the 5th dose given 4 weeks after the 4th dose.
The specific dose of mRNA vaccine will be determined according to the experimental group.
EBV mRNA vaccine infusion with a dose of 300 µg
Drug: EBV mRNA vaccine (WGc-043) Patients will receive a 300 µg dose of the EBV mRNA vaccine per administration, including 5 doses for the primary immunization regimen and subsequent optional personalized treatment. For the primary immunization, the first 4 doses will be administered weekly, with the 5th dose given 4 weeks after the 4th dose.
EBV mRNA vaccine (WGc-043)
Each subject will be infused with EBV mRNA vaccine per administration, including 5 doses for the primary immunization regimen and subsequent optional personalized treatment. For the primary immunization, the first 4 doses will be administered weekly, with the 5th dose given 4 weeks after the 4th dose.
The specific dose of mRNA vaccine will be determined according to the experimental group.
EBV mRNA vaccine infusion with a dose of 400 µg
Drug: EBV mRNA vaccine (WGc-043) Patients will receive a 400 µg dose of the EBV mRNA vaccine per administration, including 5 doses for the primary immunization regimen and subsequent optional personalized treatment. For the primary immunization, the first 4 doses will be administered weekly, with the 5th dose given 4 weeks after the 4th dose.
EBV mRNA vaccine (WGc-043)
Each subject will be infused with EBV mRNA vaccine per administration, including 5 doses for the primary immunization regimen and subsequent optional personalized treatment. For the primary immunization, the first 4 doses will be administered weekly, with the 5th dose given 4 weeks after the 4th dose.
The specific dose of mRNA vaccine will be determined according to the experimental group.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
EBV mRNA vaccine (WGc-043)
Each subject will be infused with EBV mRNA vaccine per administration, including 5 doses for the primary immunization regimen and subsequent optional personalized treatment. For the primary immunization, the first 4 doses will be administered weekly, with the 5th dose given 4 weeks after the 4th dose.
The specific dose of mRNA vaccine will be determined according to the experimental group.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Histologically or cytologically diagnosed as relapsed or refractory EBV-positive lymphoma (confirmed by in situ hybridization (ISH) or fluorescence in situ hybridization (FISH) showing EBER positivity in tumor tissue) that has failed standard treatment and lacks effective treatment options. This includes, but is not limited to, NK/T-cell lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), or other Peripheral T-cell Lymphomas (PTCL).Relapse is defined as the appearance of new lesions in the primary site or elsewhere after achieving complete remission (CR).
(1)Refractory is defined by any of the following conditions: No partial response (PR) after ≥2 cycles of treatment. No CR after ≥4 cycles of treatment. No complete remission (CR) after autologous hematopoietic stem cell transplantation.
If the best response or reason for discontinuation is progressive disease (PD), no cycle number requirements apply.
(2)Prior treatment must include:
1. Relapsed/Refractory DLBCL: Must have received at least second-line systemic therapy.
2. Relapsed/Refractory Peripheral T-cell Lymphoma: Must have received at least first-line systemic therapy.
3. Relapsed/Refractory NK/T-cell Lymphoma: Must have received a regimen based on L-asparaginase (I/II stage diseases as per the nasal NK/T-cell lymphoma CA staging system must have also received radiotherapy).
3.Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-2 points. 4.Expected survival ≥3 months. 5.At least one measurable lesion as defined by the Lymphoma Classification (2014 version), with measurable lesions defined as:
1. A lymph node lesion with a maximum long diameter \>15 mm on enhanced CT, MRI, or PET-CT.
2. An extranodal lesion with a maximum long diameter \>10 mm. 6.Adequate organ function as evidenced by the following criteria:
<!-- -->
1. No use of granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), recombinant human erythropoietin, recombinant human thrombopoietin, or blood component transfusion within 14 days prior to screening. Hemoglobin ≥80 g/L; neutrophil count \>1.0 × 10\^9/L; platelet count ≥75 × 10\^9/L.
2. Total bilirubin ≤1.5× upper limit of normal (ULN); if liver metastasis or Gilbert's syndrome present, total bilirubin ≤3× ULN.
3. ALT or AST ≤2.5× ULN; if liver metastasis, ALT or AST ≤5× ULN.
4. Serum creatinine (SCr) ≤1.5× ULN or creatinine clearance ≥50 mL/min (Cockcroft-Gault formula).
5. Prothrombin time (PT), International Normalized Ratio (INR) ≤1.5× ULN (unless using warfarin for anticoagulation).
6. Cardiac Doppler ultrasound evaluation: Left ventricular ejection fraction (LVEF) ≥50%.
7. If the investigator considers any of the above parameters below the study's lower limit due to disease progression, the patient's inclusion can be discussed with the sponsor and the CRO's medical team.
7.No plans for pregnancy during the treatment period. Female patients of childbearing potential must have a negative pregnancy test and agree to use effective contraception during the trial and for 4 months after treatment.
8.Able to understand and voluntarily sign a written informed consent form before the trial.
9.Able to communicate well with the investigator and adhere to the protocol for completing the trial.
Exclusion Criteria
2. Known to have aggressive NK-cell leukemia; central nervous system (CNS) lymphoma or CNS metastases; or associated hemophagocytic syndrome.
3. Known to have poorly controlled cardiac clinical symptoms or diseases, such as NYHA Class II heart failure or higher (see Appendix 4, section 16.4), unstable angina, myocardial infarction within the past 6 months, or clinically significant and treatable supraventricular or ventricular arrhythmias.
4. Any active autoimmune disease or history of autoimmune diseases, including but not limited to immune-related neurological diseases, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barré syndrome, myasthenia gravis, systemic lupus erythematosus (SLE), connective tissue diseases, scleroderma, inflammatory bowel diseases including Crohn's disease and ulcerative colitis, autoimmune hepatitis, toxic epidermal necrolysis (TEN), or Stevens-Johnson syndrome (except for Type 1 diabetes managed with stable doses of insulin).
5. Any uncontrolled clinical disease (e.g., respiratory, circulatory, digestive, neurological, hematological, urogenital, endocrine diseases) or mental illness (e.g., depression, schizophrenia) or other significant illnesses that, in the investigator's assessment, could hinder informed consent, interfere with the interpretation of trial results, pose risks to the subject from participation, or otherwise affect the trial's objectives.
6. History of interstitial lung disease or suspected interstitial lung disease; or presence of pulmonary abnormalities that may interfere with the detection or management of potential drug-related pulmonary toxicity during the trial.
7. Allergies to the investigational drug (including any excipients). A history of severe allergic reactions to any drugs, foods, or vaccines, such as anaphylactic shock, allergic laryngeal edema, allergic dyspnea, allergic purpura, thrombocytopenic purpura, or local allergic necrotizing reactions (Arthus reactions).
8. Any abnormalities at the injection site or permanent body art (e.g., tattoos) that the investigator believes may hinder observation of local reactions at the injection site.
9. Contraindications to intramuscular injection (see Appendix 5, section 16.5).
10. Less than 4 weeks since the last anti-tumor treatment (radiotherapy, chemotherapy, targeted therapy, immunotherapy, or local-regional therapy) or less than 2 weeks since palliative radiotherapy; patients with treatment-related adverse reactions (excluding hair loss) from previous anti-tumor therapy that have not recovered to NCI CTCAE ≤ 1 level.
11. Previous organ transplantation or allogeneic hematopoietic stem cell transplantation.
12. Systemic treatment with corticosteroids (\>10 mg/day of prednisone or equivalent dose of other glucocorticoids) or other immunosuppressants within 14 days prior to the first dose of vaccine. However, inhaled or local use of steroids and adrenal hormone replacement at doses ≤10 mg/day of prednisone in the absence of active autoimmune disease is permitted.
13. Receipt of an mRNA vaccine or similar nanoparticle delivery drugs (e.g., LNP) within 6 months prior to the first dose of vaccine.
14. Receipt of live vaccines, attenuated live vaccines, or inactivated vaccines within 4 weeks prior to the first dose of vaccine.
15. Previous administration of therapeutic vaccines or cellular immunotherapy for anti-tumor treatment.
16. Participation in other clinical trials of drugs or devices within 3 months prior to screening.
17. Blood donation or significant blood loss (\>450 mL) within 3 months prior to screening.
19. History of substance abuse or known medical, psychological, or social conditions, such as a history of alcohol or drug abuse.
20. Known infections with hepatitis B virus, hepatitis C virus, human immunodeficiency virus (HIV), or syphilis, or positive screening for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCVAb), HIV antibody, or treponemal antibody (TP) at screening:
* HBsAg(+) or HBcAb(+), with HBV DNA copy number ≥2000 IU/mL (or above the lower limit of positive detection at the study center);
* HCVAb positive, with HCV RNA ≥ ULN at the study center.
21. Patients with active tuberculosis (TB) (those suspected of having active TB must undergo chest X-ray, sputum tests, and exclude active TB through clinical symptoms and signs) or a history of active TB; or severe acute or chronic infections requiring systemic treatment.
22. Pregnant or breastfeeding women.
23. Any other factors that the investigator believes make the subject unsuitable for participation in this trial.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ruijin Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zhao Weili
MD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ruijin Hospital
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
mRNAvaccine-WGc-043
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.